Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma

This study is testing a personalized immune cell therapy made from a patient's own tumor-fighting T cells, designed to target specific mutations in the patient's liver cancer (hepatocellular carcinoma, HCC) that has progressed despite prior treatments. **You may be eligible if...** - You are 18–75 years old - You have advanced liver cancer (HCC) confirmed by biopsy - Your cancer has gotten worse after at least 2 prior systemic treatments - Your cancer can be measured on imaging scans - Your life expectancy is at least 6 months - Your overall health is reasonably good **You may NOT be eligible if...** - Your liver cancer has spread to the brain - Your liver function is severely impaired - You have active autoimmune disease - You have had a prior organ transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.